Lung Cancer

After joining a creative survivors’ group, I discovered that emotional expression, art and connection offered a profound kind of healing beyond treatment.

In July of 2025, the U.S. Food and Drug Administration approved various anti-cancer treatments and therapeutic approaches across a range of disease types.

CURE spoke with a thoracic surgeon about the impact of minimally invasive surgery for patients.

As July concludes, momentum in lung cancer research continues to build, marked by FDA decisions, trial progress, and patient-centered perspectives.

The FDA awarded orphan drug designation to VT3989 for mesothelioma, supporting the experimental cancer treatment’s development.

Self-compassion, emotional openness, and community support is incredibly important for patients currently beginning their cancer journey.

New clinical trials are advancing treatments for cutaneous T-cell lymphoma, advanced solid tumors, pediatric sarcomas and ALK-positive lung cancer.

The FDA granted fast track status to DB-1310, a HER3-targeting antibody-drug conjugate, for advanced nonsquamous non-small cell lung cancer.

Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed advanced EGFR-mutated lung cancer.

Quality-of-life in lung cancer varies, with certain treatments leading to sleep-related issues, pain, and emotional changes depending on disease stage.

In a candid interview with CURE, Terry Gillespie reflects on how her definition of survivorship has evolved from her lung cancer diagnosis to present day.

I was diagnosed with breast cancer, then lung cancer 17 years later — and both ultimately led me to make meaningful, positive changes in my life.

The U.S. FDA has approved a new test for patients with lung cancer to match the correct individuals with a targeted treatment called Zegfrovy.

The FDA approved Zegfrovy for advanced non-small cell lung cancer with EGFR exon 20 mutations after chemotherapy.

During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA approvals and priority reviews.

I entered remission from lung cancer 5.5 years ago, but faced a tough road readjusting, with ongoing physical, mental and emotional challenges.

Datroway received accelerated FDA approval for adults with EGFR+ advanced non-small cell lung cancer after EGFR-targeted and platinum chemotherapy.

Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the REZILIENT-1 and NeoADAURA trials.

Dr. Jared Weiss explained that radiation for lung cancer may ease symptoms or aim to cure, with newer targeted forms potentially boosting immune responses.

Those of us who’ve survived our cancer treatment journeys need to be role models to those who follow us.

Various trials within the small cell lung cancer space were brought to light following recent data, impacting how patients will be treated in the future.

Dr. Joshua Sabari and Jackie Herigodt discuss the Imerman Angels organization and the importance of recognizing the person behind their cancer diagnosis.

If there is ever an annual follow up CT scan that does not cause me significant anxiety, this year will be the one.

Rybrevant plus chemotherapy improved response and delayed disease progression for patients with EGFR-mutated non–small cell lung cancer after Tagrisso.

Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert oncologists.

Dr. Joshua K. Sabari and Dr. Prantesh Jain delve into key lung cancer outcomes from the 2025 ASCO Meeting that patients should be aware of.

Expert oncologists Dr. Joshua K. Sabari and Dr. Eric K. Singhi break down key updates and takeaways in lung cancer treatment following ASCO 2025.

The U.S. FDA has approved treatment with Ibtrozi for patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.

FDA granted priority review to Zepzelca plus Tecentriq for first-line maintenance in extensive-stage small cell lung cancer.

Dr. Suresh Ramalingam discusses how Tagrisso has ushered in a new era of care for patients with advanced EGFR+ non-small cell lung cancer.